Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II results with DaunoXome in non-Hodgkin's lymphoma

Nov. 15, 1996

Phase I tolerability and safety reported for Agouron's AG-331

Nov. 15, 1996

AltaRex licenses alkylating agent for North America

Nov. 15, 1996

Scotia reports progress on Foscan

Nov. 8, 1996

Scotia's radioprotectant accepted for EMEA review

Nov. 8, 1996

New preclinical results reported for marimastat

Nov. 8, 1996

Preclinical results on angiogenesis inhibitor from NeXstar

Nov. 8, 1996

RGL protein for treatment of ras-related cancers

Nov. 8, 1996

Prizm and University of Pittsburgh receive STTR grant for antimelanoma MAb

Nov. 8, 1996

Novel tumor vaccine claimed by Boehringer Ingelheim

Nov. 8, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...